Abstract
Pulmonary arterial hypertension (PAH) is a chronicand progressive disease which continues to carry an unacceptablyhigh mortality and morbidity. The nitric oxide (NO) pathwayhas been implicated in the pathophysiology and progressionof the disease. Its extremely short half-life and systemiceffects have hampered the clinical use of NO in PAH. In anattempt to circumvent these major limitations, we have developeda new NO-nanomedicine formulation. The formulationwas based on hydrogel-like polymeric composite NO-releasingnanoparticles (NO-RP). The kinetics of NO release fromthe NO-RP showed a peak at about 120 min followed by asustained release for over 8 h. The NO-RP did not affect theviability or inflammation responses of endothelial cells. TheNO-RP produced concentration-dependent relaxations of pulmonaryarteries in mice with PAH induced by hypoxia. Inconclusion, NO-RP drugs could considerably enhance thetherapeutic potential of NO therapy for PAH.
Original language | English |
---|---|
Pages (from-to) | 162-164 |
Number of pages | 3 |
Journal | Journal of Cardiovascular Translational Research |
Volume | 9 |
Issue number | 2 |
DOIs | |
Publication status | Published - 9 Mar 2016 |
Bibliographical note
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Fingerprint
Dive into the research topics of 'A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension'. Together they form a unique fingerprint.Profiles
-
Louise MacKenzie
- School of Applied Sciences - Associate Dean Education and Student Exp
- Centre for Lifelong Health
Person: Academic